Zehirli Mantarların Potansiyel Kardiyojenik Etkileri

Öz

İnsanlık tarihinin her aşamasında doğal kaynaklar insaların kurtarıcısı olmuştur. Mantarlar özellikle yagmur mevsimlerinde yoğun olarak bulunan oldukça değerli gıda kaynaklarıdır. Mantarlar beslenme durumlarına göre zehirli, yenir veya yenmez olarak gruplandırılabilir. Bu grupların olumlu veya olumsuz etkileri vardır. Bazı mantar türleri yapılarındaki biyoaktif bileşikler sayesinde farklı tıbbi özelliklere sahiptir. Özellikle insan tüketimi için mantar türlerini kullanmadan önce, bazı yenilebilir türlerde bile toksik maddeler tanımlandığı için toksikolojik profillerini karakterize etmek gerekir. Mantar zehirlenmesi (MP) olarak bilinen mycetism, uluslararası bir sağlık sorunudur. Mantarlar içerisnde ölümcül zehirlenmelere neden olanlar ve zehirlenme semptomları sınırlı olanlar vardır. Zehirli mantarlar türlerine veya neden oldukları semptomlara göre sitotoksik, nörotoksik, miyotoksik, gastroirritan mantarlar olarak birçok sınıfa ayrılır. Mantar zehirlenmesinin karaciğer, böbrekler ve merkezi sinir sistemi üzerinde ciddi toksisiteye neden olabileceği bilinmektedir. Ancak bunun kalp fonksiyonları üzerindeki etkisi henüz belirlenmemiştir. Yapılan bu araştırmada zehirli mantarlar ve görülen kardiyolojik etkileri üzerinde durulmuştur.

Anahtar Kelimeler

• Kardiyojenik etkiler
• zehirli mantarlar
• sendromlar
• yabani mantar

Potential Cardiogenic Effects of Poisonous Mushrooms

Öz

Natural resources have been the savior of people at every stage of human history. Mushrooms are very valuable food sources, especially in the rainy seasons. They can be grouped as poisonous, edible or inedible, depending on their nutritional status. These groups have positive or negative effects. Some types of mushrooms have different medicinal properties thanks to their bioactive compounds. It is necessary to characterize their toxicological profiles, especially before using mushroom species for human consumption, as toxic substances are identified even in some edible species. Mycetism, known as mushroom poisoning, is an international health problem. There are those that cause deadly poisoning and limited symptoms of poisoning in mushrooms. Poisonous mushrooms are divided into many classes as cytotoxic, neurotoxic, myotoxic, gastroirritan mushrooms according to their types or symptoms they cause. It is known that mushroom poisoning can cause serious toxicity on the liver, kidneys and central nervous system. However, its effect on heart function has not been determined yet. This study focused on poisonous mushrooms and their cardiological effects.

Anahtar Kelimeler

• Cardiogenic effects
• poisonous mushrooms
• syndromes
• wild mushroom

Kaynakça

1. Akgul, H., Sevindik, M., Coban, C. Alli, H., and Selamoglu, Z. (2017). New approaches in traditional and complementary alternative medicine practices: Auricularia auricula and Trametes versicolor. J Tradit Med Clin Natur, 6(2), 239.
2. Altintepe, L., Yazici, R., Yazici, M., Solak, Y., Topal, M., Isik, A. and Guney, I. (2014). Temporary left ventricular dysfunction in mushroom poisoning: report of three cases. Renal failure, 36,1337-1339.
3. Alves, A., Ferreira, M.G., Paulo, J., França, A. and Carvalho, A. (2001). Mushroom poisoning with Amanita phalloides—a report of four cases. Eur J Intern Med, 12, 64-66.
4. Avcı, S., Usul, E., Kavak, N., Büyükcam, F., Arslan, E.D., Genç, S. and Özkan, S. (2014). Elevated cardiac enzymes due to mushroom poisoning. Acta Biomed, 85, 275-276.
5. Azzolina, R., La Camera, G., Fiorino, L.S., Chiarenza, F., Di Francesco, A., Cavaleri DVN, Navarria, D.V., Celestri, M. and Coco, M.O. (2011). Mushroom poisoning. Acta Medica, 27, 121-124
6. Bal, C., Akgul, H., Sevindik, M., Akata, I. and Yumrutas, O. (2017). Determination of the anti-oxidative activities of six mushrooms. Fresen Environ Bull, 26, 6246-6252.
7. Bal, C., Akgul, H. and Sevindik, M. (2019). The Antioxidant potential of ethanolic extract of edible mushroom Lycoperdon molle Pers. (Agaricomycetes). Eurasian Journal of Forest Science, 7(3), 277-283.
8. Barriot, P., Masson, B. and Fournier, S. (2000). Mushroom poisoning. Rev Prat, 50, 396-400.

9. Beuhler, M. and Graeme, K.A. (2005). Overview of mushroom poisoning. Critical care toxicology: diagnosis and management of the critically poisoned patient. Philadelphia (PA): Elsevier, 2005, 1263-1275.
10. Bozdogan, A., Ulukanlı, Z., Bozok, F., Eker, T., Doğan, H.H. and Büyükalaca, S. (2018). Antioxidant Potential of Lactarius deliciosus and Pleurotus ostreatus from Amanos Mountains. Advan Life Sci, 5, 113-120.
11. Brooks, E. and Graeme, K. (2005). Gyromitra mushrooms, In: Brent, J., Wallace, K., Burkhart, K., Phillips, S. Donovan, editors. Critical care toxicology. Mosby: Elsevier, pp. 1287-1294.
12. Canli, K., Altuner, E.M., Akata, I., Turkmen, Y. and Uzek, U. (2016). In vitro antimicrobial screening of Lycoperdon lividum and determination of the ethanol extract composition by gas chromatography/mass spectrometry. Bangladesh J Pharmacol, 11, 389-394.
13. Danel, V.C., Saviuc, P.F. and Garon, D. (2001). Main features of Cortinarius spp. poisoning: a literature review. Toxicon, 39, 1053-1060.
14. De Oliveira, P. (2009). Mushroom poisoning. Med Intern, 16, 232-238.
15. Diaz, J.H. (2005). Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med, 33, 427-436.
16. Donnelly, M. and Wax, P. (2005). Cyclopeptide-containing mushrooms: deadly Amanita mushrooms. In: Brent, J., Wallace, K., Burkhart, K., Phillips, S, Donovan, editors. Critical care toxicology. Mosby: Elsevier, 1277–1285.
17. Durukan, P., Yildiz, M., Cevik, Y., Ikizceli, I., Kavalci, C. and Celebi, S. (2007). Poisoning from wild mushrooms in Eastern Anatolia region: analyses of 5 years. Hum Exp Toxicol, 26, 579-582.
18. Eigler, A., Neman, I. and Schiffl, H. (1997). Orellanus syndrome: a rare cause of uremia. Nephron, 76, 485-486.
19. Enjalbert, F., Rapior, S., Nouguier-Soulé, J., Guillon, S., Amouroux, N. and Cabot, C. (2002). Treatment of amatoxin poisoning: 20-year retrospective analysis. J Clin Toxicol, 40, 715-757.
20. Eren, S.H., Demirel, Y., Ugurlu, S., Korkmaz, I., Aktas, U. and Güven, M.K. (2010). Mushroom poisoning: retrospective analysis of 294 cases. Clinics, 65, 491-496.
21. Faulstich, H. and Wieland, T. (2019). Mushroom poisons. In Handbook of natural toxins. Routledge. Pp. 207-235.
22. Flesch, F. and Saviuc, P. (2004). Mushroom poisoning: syndromes and treatment. EMC-Méd, 1, 70-79.
23. Goldfrank, L. (2009). Mushrooms. In: Goldfrank, L. editor. Goldfranks toxicology emergencies. New York: MC Graw-Hill, pp. 1522–1536.
24. Gürgen, A., Sevindik, M., Yıldız, S. and Akgül, H. (2020). Determination of Antioxidant and Oxidant Potentials of Pleurotus citrinopileatus Mushroom Cultivated on Various Substrates. Kahramanmaraş Sütçü İmam Univ Doğa Bilim Derg, 23, 586-591.
25. Hasler, F., Bourquin, D., Brenneisen, R. and Vollenweider, F.X. (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal, 30, 331-339.
26. Jo, W.S., Hossain, M.A. and Park, S.C. (2014). Toxicological profiles of poisonous, edible, and medicinal mushrooms. Mycobiol, 42, 215-220.
27. Jr Tyler, V.E. (1963). Poisonous mushrooms. Prog Chem Toxicol, 1, 339-384.
28. Kalcik, M., Gursoy, M.O., Yesin, M., Ocal, L., Eren, H., Karakoyun, S., Astarcıoglu, M.A. and Ozkan, M. (2015). Coronary vasospasm causing acute myocardial infarction. Herz, 40, 340-344.
29. Karimi, G. and Razavi, B. (2014). Poisonous mushrooms. Clin Toxinol. the Netherlands: Springer. Pp. 587-608
30. Karimi, G., Vahabzadeh, M., Lari, P., Rashedinia, M. and Moshiri, M. (2011). “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci, 14, 308.
31. Karlson-Stiber, C. and Persson, H. (2003). Cytotoxic fungi-an overview. Toxicon, 42, 339-349.
32. Kaufmann, P. (2007). Mushroom poisonings: syndromic diagnosis and treatment. Wien Med Wochenschr Suppl, 157, 493-502.
33. Kim, K.J., Jin, S.W., Choi, B.S., Kim, J.K., Koh, Y.W., Ban, S.E. and Seo, K.S. (2016). Evaluation of the nutrition properties of Flammulina velutipes. J Mushroom, 14, 44-50.
34. Kirchmair, M., Carrilho, P., Pfab, R., Haberl, B., Felgueiras, J., Carvalho, F. and Neuhauser, S. (2012). Amanita poisonings resulting in acute, reversible renal failure: new cases, new toxic Amanita mushrooms. Nephrol Dial Transpl, 27, 1380-1386.
35. Krupodorova, T. and Sevındık, M. (2020). Antioxidant Potential and Some Mineral Contents of Wild Edible Mushroom Ramaria stricta. AgroLife Scientific Journal, 9(1), 186-191.
36. Levine, M., Ruha, A.M., Graeme, K., Brooks, D.E., Canning, J. and Curry, S.C. (2011). Toxicology in the ICU: part 3: natural toxins. Chest, 140, 1357-1370.
37. Lima, A.D., Fortes, R.C., Novaes, M.G. and Percário, S. (2012). Poisonous mushrooms; a review of the most common intoxications. Nutr Hosp, 27, 402-408.
38. Liu, Q., Zhu, M., Geng, X., Wang, H. and Ng, T.B. (2017). Characterization of polysaccharides with antioxidant and hepatoprotective activities from the edible mushroom Oudemansiella radicata. Molecules, 22, 234.
39. Lull, C., Wichers, H.J. and Savelkoul, H.F. (2005). Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm 2, 63-80.
40. Markham, J.D. and Hoff, E.C. (1953). Toxic manifestations in the antabuse-alcohol reaction: study of electrocardiographic changes. JAMA, 152, 1597-1600.
41. Mas, A. (2005). Mushrooms, amatoxins and the liver. J hepatol, 42, 166-169.
42. Méndez-Navarro, J., Ortiz-Olvera, N.X., Villegas-Ríos, M., Méndez-Tovar, L.J., Andersson, K.L., Moreno-Alcantar, R., Gallardo-Cabrera, V.E., Félix, S., Galván, C., Vargas, G., Gómez, L.M. and Dehesa-Violante, M. (2016). Hepatotoxicity from ingestion of wild mushrooms of the genus Amanita section Phalloideae collected in Mexico City: two case reports. Ann Hepatol, 10, 568-574.
43. Mhanda, F.N., Kadhila-Muandingi, N.P. and Ueitele, I.S.E. (2015). Minerals and trace elements in domesticated Namibian Ganoderma species. Afr J Biotechnol, 14, 3216-3218.
44. Michelot, D. and Toth, B. (1991). Poisoning by Gyromitra esculenta–a review. J Appl Toxıcol, 11, 235-243.
45. Mushtaq, W., Baba, H., Akata, I. and Sevindik, M. (2020). Antioxidant Potential and Element Contents of Wild Edible Mushroom Suillus granulatus. Kahramanmaraş Sütçü İmam Univ Doğa Bilim Derg, 23, 592-595.
46. Muszyńska, B., Grzywacz-Kisielewska, A., Kała, K. and Gdula-Argasińska, J. (2018). Anti-inflammatory properties of edible mushrooms: A review. Food Chem, 243, 373-381.
47. Nieminen, P., Kärjä, V. and Mustonen, A.M. (2008). Indications of hepatic and cardiac toxicity caused by subchronic Tricholoma flavovirens consumption. Food Chem Toxicol, 46, 781-786.
48. Nordt, S.P. and Manoguerra, A. (2000). 5-Year analysis of mushroom exposures in California. West J Med 173, 314.
49. Özaltun, B. and Sevindik, M. (2020). Evaluation of the effects on atherosclerosis and antioxidant and antimicrobial activities of Agaricus xanthodermus poisonous mushroom. Eur Res J, https://doi.org/10.18621/eurj.524149
50. Passie, T., Seifert, J., Schneider, U. and Emrich, H.M. (2002). The pharmacology of psilocybin. Addict Biol, 7, 357-364.
51. Peden, N.R., Pringle, S.D. and Crooks, J. (1982). The problem of psilocybin mushroom abuse. Hum Toxicol, 1, 417-424.
52. Rathee, S., Rathee, D., Rathee, D., Kumar, V. and Rathee, P. (2012). Mushrooms as therapeutic agents. Rev Bras Farmacogn, 22, 459-474.
53. Selamoglu, Z., Sevindik, M., Bal, C., Ozaltun, B., Sen, İ. and Pasdaran, A. (2020). Antioxidant, antimicrobial and DNA protection activities of phenolic content of Tricholoma virgatum (Fr.) P.Kumm. Biointerface Research in Applied Chemistry, 10(3), 5500-5506
54. Sevindik, M. (2018a). Investigation of antioxidant/oxidant status and antimicrobial activities of Lentinus tigrinus. Adv. Pharmacol. Sci. https://doi.org/10.1155/2018/1718025
55. Sevindik, M. (2018b). Antioxidant activity of ethanol extract of Daedaleopsis nitida medicinal mushroom from Turkey. Mycopath, 16(2), 47-49.
56. Sevindik, M. (2019). The novel biological tests on various extracts of Cerioporus varius. Fresen Environ Bull, 28, 3713-3717.
57. Sevindik, M., Akgul, H., Akata, I., Alli, H. and Selamoglu, Z. (2017). Fomitopsis pinicola in healthful dietary approach and their therapeutic potentials. Acta aliment, 46, 464-469.
58. Sevindik, M., Akgul, H., Bal, C. and Selamoglu, Z. (2018a). Phenolic contents, oxidant/antioxidant potential and heavy metal levels in Cyclocybe cylindracea. Indian J Pharm Educ, 52, 437-441.
59. Sevindik, M., Akgul, H., Dogan, M., Akata, I. and Selamoglu, Z. (2018b). Determination of antioxidant, antimicrobial, DNA protective activity and heavy metals content of Laetiporus sulphureus. Fresen Environ Bull, 27, 1946-1952.
60. Sevindik, M. (2019). Wild Edible Mushroom Cantharellus cibarius as a Natural Antioxidant Food. Turkish Journal of Agriculture-Food Science and Technology, 7(9), 1377-1381.
61. Sevindik, M. and Akata, I. (2020). Antioxidant, oxidant potentials and element content of edible wild mushroom Helvella leucopus. Indian Journal of Natural Products and Resources (IJNPR)[Formerly Natural Product Radiance (NPR)], 10(4), 266-271.
62. Sevindik, M. (2020). Antioxidant and antimicrobial capacity of Lactifluus rugatus and its antiproliferative activity on A549 cells. Indian Journal of Traditional Knowledge (IJTK), 19(2), 423-427.
63. Sevindik, M., Akgul, H., Selamoglu, Z. and Braidy, N. (2020). Antioxidant and Antigenotoxic Potential of Infundibulicybe geotropa Mushroom Collected from Northwestern Turkey. Oxidative Medicine and Cellular Longevity, https://doi.org/10.1155/2020/5620484
64. Stolman, A. (2013). Progress in chemical toxicology (Vol. 3). Elsevier.
65. Süfer, O., Bozok, F. and Demir, H. (2016). Usage of edible mushrooms in various food products. Turjaf, 4, 144-149.
66. Tegzes, J.H. and Puschner, B. (2002). Toxic mushrooms. Vet Clin North Am Small Anim Pract, 32, 397-407.
67. Tsujikawa, K., Mohri, H., Kuwayama, K., Miyaguchi, M., Iwata, Y., Gohda, A., Fukushima, S., Inouea, H. and Kishi, T. (2006). Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. Forensic Sci Int, 164,172-178.
68. Unverir, P., Soner, B.C., Dedeoglu, E., Karcioglu, O., Boztok, K. and Tuncok, Y. (2007). Renal and hepatic injury with elevated cardiac enzymes in Amanita phalloides poisoning: a case report. Hum Exp Toxicol, 26, 757-761.
69. Vanooteghem, S., Arts, A., Decock, S., Pieraerts, P., Meersseman, W., Verslype, C. and Van, P.H. (2014). Four patients with Amanita Phalloides poisoning. Acta Gastro-Ent Belg, 77, 353-356.
70. Vogel, G., Tuchweber, B., Trost, W. and Mengs, U. (1984). Protection by silibinin against Amanita phalloides intoxication in beagles. Toxıcol Appl Pharm, 73, 355-362.
71. Wasser, S.P. (2017). Medicinal mushrooms in human clinical studies. Part I. Anticancer, oncoimmunological, and immunomodulatory activities: a review. Int J Med Mushrooms, 19, 279-317
72. Wessely, M., Schönermarck, U., Raziorrouh, B., Jung, M.C. and Samtleben, W. (2007). Orellanus syndrome: a rare cause of acute renal failure. Deut Med Wochenschr, 132,1880-1882.
73. White, J., Warrell, D., Eddleston, M., Currie, B.J., Whyte, I.M. and Isbister, G.K. (2003). Clinical toxinology—where are we now? antivenoms. J Toxicol Clin Toxicol, 41, 263-276.
74. White, J., Weinstein, S.A., De Haro, L., Bédry, R., Schaper, A., Rumack, B.H. and Zilker, T. (2019). Mushroom poisoning: A proposed new clinical classification. Toxicon 157, 53-65.
75. Yardan, T., Baydin, A., Eden, A.O., Akdemir, H.U., Aygun, D., Acar, A. and Arslan, A. (2010). Wild mushroom poisonings in the Middle Black Sea region in Turkey: analyses of 6 years. Hum Exp Toxicol, 29, 767-771.